天津医药 ›› 2022, Vol. 50 ›› Issue (5): 471-475.doi: 10.11958/20212362

• 实验研究 • 上一篇    下一篇

依达拉奉右莰醇通过抑制TLR4/NF-κB信号通路减轻实验性自身免疫性脑脊髓炎小鼠炎症反应#br#

晚丽,李作孝△   

  1. 西南医科大学附属医院神经内科(邮编646000)
  • 收稿日期:2021-10-21 修回日期:2022-01-09 出版日期:2022-05-15 发布日期:2022-07-04
  • 基金资助:
    泸州市人民政府-西南医科大学科技战略合作基金项目(2018LZXNYD-ZK17)

Edaravone dexborneol reduces inflammation in mice with experimental autoimmune encephalomyelitis by inhibiting TLR4/NF-κB signaling pathway

WAN Li, LI Zuoxiao△   

  1. Department of Neurology, the Affiliated Hospital of Southwest Medical University, Luzhou 646000, China
  • Received:2021-10-21 Revised:2022-01-09 Published:2022-05-15 Online:2022-07-04

摘要: 目的 探讨依达拉奉右莰醇对实验性自身免疫性脑脊髓炎(EAE)小鼠炎症反应的影响及其机制。方法 30只雌性C57BL/6小鼠随机分为空白组、模型组、依达拉奉右莰醇干预组各10只。除空白组外,其余2组小鼠均采用髓鞘少突胶质细胞糖蛋白35-55(MOG35-55)多肽诱导EAE模型。从造模次日开始,依达拉奉右莰醇干预组腹腔注射依达拉奉右莰醇12.5 mg/kg,空白组及模型组腹腔注射等量生理盐水,1次/d,连续14 d。观察小鼠发病情况,并行神经功能障碍评分;HE和LFB染色观察脊髓组织病理改变;实时荧光定量PCR检测脑组织匀浆中白细胞介素(IL)-1β、IL-6及肿瘤坏死因子(TNF)-α mRNA表达水平;蛋白免疫印迹法检测脊髓组织中Toll样受体4(TLR4)、核因子κB p65(NF-κB p65)蛋白表达水平。结果 空白组小鼠均未发病,其余2组小鼠不同程度发病。与模型组相比,依达拉奉右莰醇干预组小鼠的发病潜伏期、高峰期延迟,高峰期神经功能障碍评分降低(P<0.01)。空白组小鼠脊髓组织未见异常;模型组脊髓组织大量炎性细胞浸润、髓鞘结构紊乱;依达拉奉右莰醇干预组较模型组的炎性细胞浸润减少、髓鞘结构紊乱情况改善。与空白组相比,其余2组小鼠脑组织匀浆中IL-1β、IL-6、TNF-α mRNA表达水平以及脊髓组织中TLR4、NF-κB p65蛋白表达水平显著升高,以依达拉奉右莰醇干预可逆转建模引起的上述改变(P<0.05)。结论 依达拉奉右莰醇可减轻EAE小鼠炎症反应,其机制可能与抑制TLR4/NF-κB信号通路活化有关。

关键词: 脑脊髓炎, 自身免疫性, 实验性;Toll样受体4;NF-κB;炎症;白细胞介素类;肿瘤坏死因子α;依达拉奉右莰醇;TLR4/NF-κB信号通路

Abstract: Objective To investigate the effect and mechanism of edaravone dexborneol on the inflammatory response in mice with experimental autoimmune encephalomyelitis (EAE). Methods Thirty female C57BL/6 mice were randomly divided into the blank group, the model group and the edaravone dexborneol intervention group, with 10 mice in each group. Except for the blank group, EAE model was induced by myelin oligodendrocyte glycoprotein 35-55 (MOG35-55) polypeptide in the other two groups. From the day after modeling, mice in the edaravone dexborneol intervention group were intraperitoneally injected with edaravone dexborneol 12.5 mg/kg, while the mice in the blank group and the model group were intraperitoneally injected with the equal amount normal saline, once a day for consecutive 14 days. The behavioral changes of mice were observed, and neurological dysfunction scores were performed. HE and LFB staining were used to detect spinal cord pathological changes. The mRNA expression levels of interleukin (IL)-1β, IL-6 and tumor necrosis factor-α (TNF-α) in brain homogenate were detected by real-time fluorescence quantitative PCR. The protein expression levels of Toll-like receptor 4 (TLR4) and nuclear factor κB p65 (NF-κB p65) in spinal cord tissue were detected by Western blot assay. Results None of the mice in the blank group had the disease, and the other two groups of mice had different degrees of disease. Compared with the model group, the incubation period and peak period were delayed in the edaravone dexborneol intervention group, and neurological deficit scores in peak period decreased (P<0.01). No abnormality was found in spinal cord tissue structure in mice of the blank group, and a large number of inflammatory cell infiltration, myelin structure disorder were found in the spinal cord tissue of the model group. Compared with the model group, inflammatory cell infiltration was reduced and myelin structure disorder was improved in the edaravone dexborneol intervention group. Compared with the blank group, the IL-1β, IL-6, TNF-α mRNA expression levels in brain tissue homogenate and the TLR4, NF-κB p65 protein expression levels in spinal cord tissue were significantly increased in the other two groups (P<0.05). After intervention with edaravone dexborneol, the above changes induced by modeling were reversed (P<0.05). Conclusion Edaravone dexborneol can effectively reduce the inflammatory response in EAE mice, and its mechanism may be related to the inhibition of TLR4/NF-κB signaling pathway activation.

Key words: encephalomyelitis, autoimmune, experimental, Toll-like receptor 4, NF-kappa B, inflammation, interleukins, tumor necrosis factor-alpha, edaravone dexborneol, TLR4/NF-κB signaling pathway

中图分类号: